echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > J Rheumatol: Risk and consequences of vertebral fractures in patients with strong syllitis

    J Rheumatol: Risk and consequences of vertebral fractures in patients with strong syllitis

    • Last Update: 2020-05-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The study was designed to compare long-term prevalence, morbidity and outcomes of vertebral fractures (
    VF) in patients with strong syllitis (
    AS) and matching control group, including the effects of out-of-the-joint manifestations (
    EAM) andosteoporosisresearchers conducted a statewide observational study using2,321patients withASand22,976 controls on online health data from2,321 1980-2015 Data analysis was performed using morbidity (per 1000 years) and ratios (
    IRR ), multifactory
    Cox proportional risk regression, and Kaplan-Meier survival curve During the median follow-up 13.92 years (
    IQR 7.58 , 2 1.67 ), the incidence of VF and new VF in patients of AS were higher than those of the control group (
    9.3 percent vs 2.5 percent, 6.8 percent .9 percent, respective ly, Compared to the control group, the risk of VF in patients with AS was increased after adjusting age, sex, and osteoporosis (
    HR s 2.55 ; 95 % CI : 2.11 , 3.09 ) and continued throughout the study period Patients with AS were younger 5 years old (
    p-0.008 ) for the first time VF compared to the corresponding control group( and more likely to have VF again (
    IRR ? 4.64; 95 % CI : 4.54 , 4.75 ) After adjusting for age, sex, osteoporosis and VF status, the overall mortality rate of AS patients was comparable to that of the control group (
    HR ?0.90 ; 95 % CI : 0.80 , 1.01 ) began treatment TNFi , the significant increase dyslecostofability of VF in patients AS has not changed Although AS patients with first-
    VF are younger than the control group, this does not increase the risk of death
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.